Product Name |
CDK1 |
CDK2 |
CDK3 |
CDK4 |
CDK5 |
CDK6 |
CDK7 |
CDK8 |
CDK9 |
CDK14 |
CDK16 |
CLK |
CDK1 Selectivity |
Purity |
Ro-3306 |
CDK1, Ki: 20 nM
CDK1/cyclinB1, Ki: 35 nM
CDK1/cyclin A, Ki: 110 nM
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
98.54% |
PF 477736 |
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
99.21% |
Cucurbitacin E |
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
99.92% |
Cdk1/2 Inhibitor III |
Cdk1/cyclin B, IC50: 2.1 μM
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
|
Abemaciclib |
CDK1/cyclinB1, IC50: 1627 nM
|
CDK2/cyclinE, IC50: 504 nM
|
|
Cdk4/cyclin D1, IC50: 2 nM
|
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
|
CDK6/cyclinD1, IC50: 10 nM
|
CDK7/Mat1/cyclinH1, IC50: 3910 nM
|
|
CDK9/cyclinT1, IC50: 57 nM
|
|
|
|
Pan Inhibitor
|
99.69% |
Dinaciclib |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.36% |
hSMG-1 inhibitor 11j |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Abemaciclib methanesulfonate |
CDK1/cyclinB1, IC50: 1627 nM
|
CDK2/cyclinE, IC50: 504 nM
|
|
Cdk4/cyclin D1, IC50: 2 nM
|
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
|
CDK6/cyclinD1, IC50: 10 nM
|
CDK7/Mat1/cyclinH1, IC50: 3910 nM
|
|
CDK9/cyclinT1, IC50: 57 nM
|
|
|
|
Pan Inhibitor
|
≥98.0% |
Flavopiridol |
|
|
|
CDK4/Cyc D1, IC50: 100 nM
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.72% |
Seliciclib |
cdc2/cyclin B, IC50: 0.65 μM
|
cdk2/cyclin A, IC50: 0.7 μM
Cdk2/cyclin E2, IC50: 0.7 μM
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥98.0% |
SNS-032 |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.50% |
AZD-5438 |
cdk1-cyclin B1, IC50: 16 nM
|
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
|
|
cdk4-cyclin D1, IC50: 449 nM
|
|
cdk6-cyclin D3, IC50: 21 nM
|
cdk7-cyclin H, IC50: 821 nM
|
|
cdk9-cyclin T, IC50: 20 nM
|
|
|
|
Pan Inhibitor
|
99.37% |
Flavopiridol Hydrochloride |
|
|
|
CDK4/Cyc D1, IC50: 100 nM
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥95.0% |
AT7519 |
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
CDK9/Cyclin T, IC50: 10 nM
|
|
|
|
Pan Inhibitor
|
99.40% |
GSK 3 Inhibitor IX |
Cdk1/cyclin B, IC50: 320 nM
|
cdk2/cyclin A, IC50: 300 nM
|
|
Cdk4/cyclin D1, IC50: 10 μM
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥98.0% |
JNJ-7706621 |
Cdk1/cyclin B, IC50: 9 nM
|
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
|
CDK3/Cyclin E, IC50: 58 nM
|
Cdk4/cyclin D1, IC50: 253 nM
|
|
CDK6/cyclinD1, IC50: 175 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
99.96% |
Kenpaullone |
Cdk1/cyclin B, IC50: 0.4 μM
|
cdk2/cyclin A, IC50: 0.68 μM
CDK2/cyclinE, IC50: 7.5 μM
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥97.0% |
Samuraciclib hydrochloride |
|
cdk2/cyclin A, IC50: 578 nM
|
|
|
CDK5/p35NCK, IC50: 9.4 μM
|
|
CDK7/cyclin H, IC50: 41 nM
|
|
|
|
|
|
Pan Inhibitor
|
99.98% |
CGP60474 |
CDK1-Cyclin B, IC50: 26 nM
|
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
|
|
CDK4/cyclin D, IC50: 216 nM
|
|
|
CDK7/cyclin H, IC50: 200 nM
|
|
|
|
|
|
Pan Inhibitor
|
98.70% |
CVT-313 |
Cdk1/cyclin B, IC50: 4.2 μM
|
cdk2/cyclin A, IC50: 0.5 μM
|
|
Cdk4/cyclin D1, IC50: 215 μM
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.76% |
Milciclib |
cyclin B/CDK1, IC50: 398 nM
|
cyclin A/CDK2, IC50: 45 nM
cyclin E/CDK2, IC50: 363 nM
|
|
cyclin D1/CDK4, IC50: 160 nM
|
|
|
cyclin H/CDK7, IC50: 150 nM
|
|
|
|
|
|
Pan Inhibitor
|
99.92% |
THZ2 |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥95.0% |
BMS-265246 |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.28% |
R547 |
Cdk1/cyclin B, Ki: 2 nM
Cdk1/cyclin B, IC50: 0.2 nM
|
CDK2/cyclinE, Ki: 3 nM
cdk2/cyclin A, IC50: 0.1 nM
CDK2/cyclinE, IC50: 0.4 nM
|
CDK3/Cyclin E, IC50: 0.8 nM
|
|
|
cdk6/cyclin D3, IC50: 4 nM
|
CDK7/cyclin H, IC50: 171 nM
|
|
|
|
|
|
Pan Inhibitor
|
99.66% |
LDC000067 |
cdk1-cyclin B1, IC50: 5513 nM
|
cdk2-cyclin A, IC50: 2441 nM
|
|
cdk4-cyclin D1, IC50: 9242 nM
|
|
|
|
|
CDK9- Cyclin T1, IC50: 44 nM
|
|
|
|
Pan Inhibitor
|
98.58% |
NG 52 |
cdc2-cyclin B, IC50: 0.34 μM
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.97% |
Purvalanol A |
cdc2-cyclin B, IC50: 4 nM
|
cdk2-cyclin E, IC50: 35 nM
cdk2-cyclin A, IC50: 70 nM
|
|
cdk4-cyclin D1, IC50: 850 nM
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.11% |
Roniciclib |
Cdk1/cyclin B, IC50: 7 nM
|
|
|
CDK4/cyclin D, IC50: 11 nM
|
|
|
CDK7/Cyclin H/MAT1, IC50: 25 nM
|
|
CDK9/cyclinT1, IC50: 5 nM
|
|
|
|
Pan Inhibitor
|
98.89% |
PHA-767491 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.91% |
CDK2-IN-4 |
Cdk1/cyclin B, IC50: 86 μM
|
cdk2/cyclin A, IC50: 44 nM
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥97.0% |
PHA-793887 |
Cdk1/cyclin B, IC50: 60 nM
|
cdk2/cyclin A, IC50: 8 nM
CDK2/cyclinE, IC50: 8 nM
|
|
Cdk4/cyclin D1, IC50: 62 nM
|
|
|
CDK7/cyclin H, IC50: 10 nM
|
|
CDK9/cyclinT1, IC50: 138 nM
|
|
|
|
Pan Inhibitor
|
99.25% |
(R)-CR8 trihydrochloride |
CDK1/cyclinB1, IC50: 0.09 μM
|
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
|
|
|
|
|
CDK7/cyclin H, IC50: 1.1 μM
|
|
CDK9/Cyclin T, IC50: 0.18 μM
|
|
|
|
Pan Inhibitor
|
99.02% |
Atuveciclib |
CDK1/CycB(h), IC50: 1100 nM
|
CDK2/CycE(h), IC50: 1000 nM
|
CDK3/CycE(h), IC50: 890 nM
|
|
CDK5/p35(h), IC50: 1600 nM
|
|
|
|
CDK9/CycT1, IC50: 13 nM
CDK9/CycT1(h), IC50: 6 nM
|
|
|
|
Pan Inhibitor
|
99.20% |
SU9516 |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.83% |
Purvalanol B |
cdc2/cyclin B, IC50: 6 nM
cyclin dependent kinase 1-cyclinB, IC50: 6 nM
|
cdk2/cyclin A, IC50: 6 nM
CDK2/cyclinE, IC50: 9 nM
|
|
Cdk4/cyclin D1, IC50: 10000 nM
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥97.0% |
Riviciclib hydrochloride |
CDK1-Cyclin B, IC50: 0.079 μM
|
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.500 μM
|
|
cdk4-cyclin D1, IC50: 0.063 μM
|
|
cdk6-cyclin D3, IC50: 0.396 μM
|
|
|
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
|
|
|
|
Pan
|
98.33% |
CDKI-73 |
CDK1, IC50: 8.17 nM
CDK1, Ki: 4 nM
|
CDK2, IC50: 3.27 nM
CDK2, Ki: 3 nM
|
|
|
|
|
CDK7, IC50: 134.26 nM
CDK7, Ki: 91 nM
|
|
CDK9, IC50: 5.78 nM
CDK9, Ki: 4 nM
|
|
|
|
Pan Inhibitor
|
99.58% |
AMG 925 |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.33% |
(R)-CR8 |
Cdk1/cyclin B, IC50: 0.09 μM
|
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
|
|
|
|
|
CDK7/cyclin H, IC50: 1.1 μM
|
|
CDK9/Cyclin T, IC50: 0.18 μM
|
|
|
|
Pan Inhibitor
|
≥98.0% |
AT7519 Hydrochloride |
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
CDK9/Cyclin T, IC50: 10 nM
|
|
|
|
Pan Inhibitor
|
99.99% |
BS-181 hydrochloride |
|
CDK2/Cyc E, IC50: 0.88 μM
|
|
|
|
|
CDK7/CycH/MAT1, IC50: 0.021 μM
|
|
|
|
|
|
Pan Inhibitor
|
≥99.0% |
MC180295 |
CDK1-Cyclin B, IC50: 138 nM
|
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
|
CDK3-Cyclin E, IC50: 399 nM
|
CDK4-Cyclin D, IC50: 112 nM
|
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
|
cdk6-cyclin D3, IC50: 712 nM
|
CDK7-CycH/MAT1, IC50: 555 nM
|
|
CDK9- Cyclin T1, IC50: 5 nM
|
|
|
|
Pan Inhibitor
|
98.47% |
Voruciclib hydrochloride |
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
|
|
|
|
|
|
|
|
CDK9/CycT1, Ki: 1.68 nM
CDK9/cyc T2, Ki: 0.626 nM
|
|
|
|
Pan Inhibitor
|
98.20% |
Lerociclib dihydrochloride |
CDK1/cyclinB1, IC50: 2.4 μM
|
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
|
|
Cdk4/cyclin D1, IC50: 1 nM
|
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
|
cdk6/cyclin D3, IC50: 2 nM
|
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
|
|
CDK9/Cyclin T, IC50: 28 nM
|
|
|
|
Pan Inhibitor
|
98.45% |
K00546 |
Cdk1/cyclin B, IC50: 0.6 nM
|
cdk2/cyclin A, IC50: 0.5 nM
|
|
|
|
|
|
|
|
|
|
CLK1, IC50: 8.9 nM
CLK3, IC50: 29.2 nM
|
Pan Inhibitor
|
98.78% |
JSH-150 |
Cdk1/cyclin B, IC50: 1.34 μM
|
cdk2/cyclin A, IC50: 2.86 μM
|
|
|
|
|
CDK7/Cyclin H/MNAT1, IC50: 1.72 μM
|
|
CDK9/cyclinT1, IC50: 1 nM
|
CDK14/Cyclin Y, IC50: 1.68 μM
|
CDK16/Cyclin Y, IC50: 292 nM
|
|
Pan Inhibitor
|
98.36% |
NU2058 |
|
CDK2, IC50: 17 μM
CDK2, Ki: 12 μM
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.01% |
Voruciclib |
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
|
|
|
|
|
|
|
|
CDK9/cyc T2, Ki: 0.626 nM
CDK9/CycT1, Ki: 1.68 nM
|
|
|
|
Pan Inhibitor
|
99.52% |
Alsterpaullone |
Cdk1/cyclin B, IC50: 35 nM
|
cdk2/cyclin A, IC50: 15 nM
CDK2/Cyc E, IC50: 200 nM
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥98.0% |
NVP-LCQ195 |
Cdk1/cyclin B, IC50: 2 nM
|
cdk2/cyclin A, IC50: 2 nM
CDK2/cyclinE, IC50: 5 nM
|
CDK3/Cyclin E, IC50: 42 nM
|
|
Cdk5/p25, IC50: 1 nM
CDK5/p35, IC50: 1 nM
|
cdk6/cyclin D3, IC50: 187 nM
|
CDK7/Cyclin H/MAT1, IC50: 3564 nM
|
|
CDK9/cyclinT1, IC50: 15 nM
|
|
|
|
Pan Inhibitor
|
99.80% |
CAN508 |
Cdk1/cyclin B, IC50: 44 μM
|
CDK2/cyclinE, IC50: 20 μM
cdk2/cyclin A, IC50: 69 μM
|
|
Cdk4/cyclin D1, IC50: 13.5 μM
|
|
|
CDK7/cyclin H, IC50: 26 μM
|
|
CDK9/cyclinT1, IC50: 0.35 μM
|
|
|
|
Pan Inhibitor
|
|
NU6140 |
CDK1-Cyclin B, IC50: 6.6 μM
|
cdk2-cyclin A, IC50: 0.41 μM
|
|
CDK4-Cyclin D, IC50: 5.5 μM
|
|
|
cdk7-cyclin H, IC50: 3.9 μM
|
|
|
|
|
|
Pan Inhibitor
|
≥99.0% |
NU6102 |
Cdk1/cyclin B, IC50: 9.5 nM
|
CDK2/cyclin A3, IC50: 5.4 nM
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥95.0% |
AMG 925 HCl |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.01% |
5-Iodo-indirubin-3'-monoxime |
Cdk1/cyclin B, IC50: 25 nM
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.50% |
AT7519 trifluoroacetate |
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
CDK9/Cyclin T, IC50: 10 nM
|
|
|
|
Pan Inhibitor
|
98.16% |
CDK4/6-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Riviciclib |
CDK1-Cyclin B, IC50: 0.079 μM
|
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.540 μM
|
|
cdk4-cyclin D1, IC50: 0.063 μM
|
|
cdk6-cyclin D3, IC50: 0.396 μM
|
|
|
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
|
|
|
|
Pan Inhibitor
|
|
Lerociclib |
CDK1/cyclinB1, IC50: 2.4 μM
|
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
|
|
Cdk4/cyclin D1, IC50: 1 nM
|
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
|
cdk6/cyclin D3, IC50: 2 nM
|
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
|
|
CDK9/Cyclin T, IC50: 28 nM
|
|
|
|
Pan Inhibitor
|
|
NU6027 |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Indirubin-3'-monoxime-5-sulphonic acid |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Indirubin-5-sulfonate |
Cdk1/cyclin B, IC50: 55 nM
|
cdk2/cyclin A, IC50: 35 nM
CDK2/cyclinE, IC50: 150 nM
|
|
Cdk4/cyclin D1, IC50: 300 nM
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
hSMG-1 inhibitor 11e |
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Desmethylglycitein |
|
|
|
|
|
|
|
|
|
|
|
|
Inhibitor
|
≥95.0% |